目的 采用網(wǎng)絡(luò)藥理學(xué)及分子對(duì)接技術(shù)探討丹參治療缺血性腸病的作用機(jī)制。方法 運(yùn)用TCMSP數(shù)據(jù)庫(kù)獲得丹參的有效成分和預(yù)測(cè)靶點(diǎn)，并在UniProt數(shù)據(jù)庫(kù)中進(jìn)行標(biāo)準(zhǔn)化處理，從而獲得相應(yīng)的藥物靶點(diǎn)基因。利用GeneCards和OMIM數(shù)據(jù)庫(kù)獲得缺血性腸病的靶點(diǎn)基因。將藥物的靶點(diǎn)基因及疾病的靶點(diǎn)基因?qū)腠f恩圖制作分析平臺(tái)獲得丹參治療缺血性腸病的潛在作用靶點(diǎn)。利用Cytoscape3.8.2軟件構(gòu)建“藥物–成分–靶點(diǎn)–疾病”網(wǎng)絡(luò)。將潛在的作用靶點(diǎn)導(dǎo)入STRING數(shù)據(jù)庫(kù)進(jìn)行蛋白質(zhì)相互作用（PPI）網(wǎng)絡(luò)分析。運(yùn)用Metascape數(shù)據(jù)庫(kù)對(duì)潛在作用靶點(diǎn)進(jìn)行基因本體（GO）功能富集分析和京都基因與基因組百科全書(shū)（KEGG）通路分析。最后運(yùn)用AutoDock vina、PyMOL等軟件對(duì)丹參有效化學(xué)成分和關(guān)鍵的靶點(diǎn)基因進(jìn)行對(duì)接驗(yàn)證。結(jié)果 共獲得了65個(gè)丹參的活性化合物成分，139個(gè)丹參的作用靶點(diǎn)基因和2 799個(gè)缺血性腸病的作用靶點(diǎn)基因，其中丹參與缺血性腸病共同作用靶點(diǎn)為84個(gè)。構(gòu)建網(wǎng)絡(luò)發(fā)現(xiàn)木犀草素、丹參酮II_A、新隱丹參酮II等為丹參作用于缺血性腸病的主要化合物成分。通過(guò)PPI網(wǎng)絡(luò)分析發(fā)現(xiàn)蛋白激酶B1（Akt1）、腫瘤壞死因子（TNF）、雌激素受體1（ESR1）、原癌基因（JUN）和溶質(zhì)載體家族6成員3（SLC6A3）等為關(guān)鍵的靶點(diǎn)基因。富集結(jié)果顯示細(xì)胞對(duì)氮化合物的反應(yīng)、細(xì)胞對(duì)有機(jī)環(huán)化合物的反應(yīng)和細(xì)胞對(duì)有機(jī)氮化合物的反應(yīng)等生物學(xué)過(guò)程調(diào)控脂質(zhì)與動(dòng)脈粥樣硬化、流體剪切應(yīng)力與動(dòng)脈粥樣硬化、磷脂酰肌醇3激酶（PI3K）/Akt信號(hào)通路、環(huán)鳥(niǎo)苷酸–蛋白激酶G（cGMP-PKG）信號(hào)通路、TNF信號(hào)通路等信號(hào)通路對(duì)缺血性腸病起到治療作用。分子對(duì)接的結(jié)果表明丹參的有效化學(xué)成分和缺血性腸病的靶點(diǎn)基因具有良好的結(jié)合性。結(jié)論 丹參可能通過(guò)木犀草素、丹參酮II_A、新隱丹參酮II等有效成分，作用于Akt1、TNF和ESR1等核心靶點(diǎn)基因，調(diào)控脂質(zhì)與動(dòng)脈粥樣硬化、流體剪切應(yīng)力與動(dòng)脈粥樣硬化等信號(hào)通路對(duì)缺血性腸病起到治療作用。

Objective To investigate the mechanism of action of Salvia miltiorrhiza in treatment of ischemic enteropathy by using network pharmacology and molecular docking technology. Methods The active components and predicted targets of Salvia miltiorrhiza were obtained by TCMSP database, and standardized in UniProt database to obtain the corresponding drug target genes. Target genes of ischemic bowel disease were obtained by GeneCards and OMIM databases. Drug target genes and disease target genes were introduced into the Venn diagram analysis platform to obtain potential targets of Salvia miltiorrhiza in treatment of ischemic bowel disease. Build a “Drug-ingredient-target-disease” network using Cytoscape3.8.2 software. Potential targets were imported into STRING database for protein interaction (PPI) network analysis. Metascape database was used for GO functional enrichment analysis and KEGG pathway analysis for potential targets. Finally, AutoDock vina, PyMOL and other software were used to analyze and verify the effective chemical components and key target genes of Salvia miltiorrhiza. Results A total of 65 active compounds of Salvia miltiorrhiza, 139 target genes of Salvia miltiorrhiza and 2 799 target genes of ischemic bowel disease were obtained, among which 84 target genes of Salvia miltiorrhiza and ischemic bowel disease were combined. Network construction revealed that luteolin, tanshinone II_A, and neocryptotanshinone II were the main compound components of Salvia miltiorrhiza acting in ischemic bowel disease. Akt1, TNF, ESR1, JUN, and SLC6A3 were identified as key target genes by PPI network analysis. The enrichment results showed that biological processes such as cellular response to nitrogen compounds, cellular response to organocyclic compounds, and cellular response to organic nitrogen compounds regulated lipids and atherosclerosis, fluid shear stress and atherosclerosis, PI3K/Akt signaling pathway, cGMP PKG signaling pathway, and TNF signaling pathway signaling pathways play a therapeutic role in ischemic bowel disease. The results of molecular docking indicated that the active chemical components of Salvia miltiorrhiza and the target genes of ischemic enteropathy have good binding. Conclusion Salvia miltiorrhiza may act on core target genes such as Akt1, TNF, and ESR1 to regulate lipids and atherosclerosis, fluid shear stress and atherosclerosis, through the active ingredients such as luteolin, tanshinone II_A and neocryptotanshinone II and other signaling pathways play a therapeutic role in ischemic bowel disease.

R285

深圳市龍崗區(qū)經(jīng)濟(jì)與科技發(fā)展專(zhuān)項(xiàng)資金醫(yī)療衛(wèi)生科技計(jì)劃項(xiàng)目(LGWJ2021-75)